Functional influenza virus like particles (VLPs)
The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
1. A vaccine comprising an influenza VLP, wherein said VLP comprises influenza proteins, wherein the influenza proteins consist of M1, HA and NA proteins; wherein the M1 protein is derived from a different influenza virus strain than the HA and NA proteins; wherein the influenza proteins are insect-cell expressed, and wherein the M1 protein is from an avian influenza strain.
2. The vaccine of claim 1 , wherein said HA exhibits hemagglutinin activity and/or said NA exhibits neuraminidase activity.
3. The vaccine of claim 1 , wherein the HA and NA proteins are from a seasonal influenza virus.
4. The vaccine of claim 3 , wherein said seasonal influenza virus is a type A influenza virus.
5. The vaccine of claim 3 , wherein said seasonal influenza virus is a type B influenza virus.
6. The vaccine of claim 1 , wherein said influenza VLP comprises avian influenza HA and NA proteins.
7. The vaccine of claim 6 , wherein said avian influenza virus HA and NA proteins are H5N1.
8. The vaccine of claim 6 , wherein said avian influenza virus HA and NA proteins are H9N2.
9. The vaccine of claim 1 , wherein said influenza VLP is formulated with an adjuvant or immune stimulator.
10. The vaccine of claim 9 , wherein said adjuvant comprises paucilamellar nonphospholipid vesicles.
11. A method of inducing substantial immunity to influenza virus infection in an animal susceptible to influenza, comprising administering at least one effective dose of the vaccine of claim 1 .
12. The method of claim 11 , wherein said HA exhibits hemagglutinin activity and/or said NA exhibits neuraminidase activity.
13. The method of claim 11 , wherein said animal is a human.
14. The method of claim 11 , wherein said method comprises administering to an animal said influenza vaccine orally, intradermally, intranasally, intramuscularly, intraperitoneally, intravenously, or subcutaneously.
15. The vaccine of claim 1 wherein the insect cell is an Sf9 cell.
16. The vaccine of claim 1 wherein the HA protein is selected from the group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15 and H16.
17. The vaccine of claim 1 wherein the NA protein is selected from the group consisting of N1, N2, N3, N4, N5, N6, N7, N8 and N9.